This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quitting Caffeine for Better Glucose Metabolism

This study has been completed.
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Identifier:
First received: December 10, 2009
Last updated: February 3, 2011
Last verified: February 2011
This project is a pilot study of caffeine abstinence in coffee-drinkers who have type 2 diabetes. Evidence suggests that caffeine may impair the control of glucose levels, especially in those people who have type 2 diabetes. Eliminating caffeinated beverages from the diet might improve glucose control, but the difficulty of quitting is unknown. This pilot study will follow a small number of type 2 diabetic patients for three months after a brief intervention designed to help people quit caffeine. Data on success with maintaining abstinence and on changes in glucose control will be collected.

Condition Intervention Phase
Diabetes Mellitus, Type 2 Behavioral: Caffeine abstinence Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Quitting Caffeine for Better Glucose Metabolism

Resource links provided by NLM:

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Caffeine abstinence [ Time Frame: baseline, 2 weeks, 1, 2, and 3 months ]

Secondary Outcome Measures:
  • HbA1c [ Time Frame: Baseline, 3 months ]

Estimated Enrollment: 25
Study Start Date: December 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Caffeine abstinence
    Brief instruction on beginning and maintaining caffeine abstinence.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 6-month history of type 2 diabetes
  • impaired chronic glucose control (HbA1c >= 7%)
  • daily consumption of 250 mg caffeine or more in coffee, tea, and other caffeinated beverages

Exclusion Criteria:

  • use of exogenous insulin
  • use of non-diabetes medications that impact glucose metabolism
  • medical of psychiatric history that prevents participation or increases risk
  • current pregnancy
  • current participation in other clinical trials
  • deemed unable to comply with the study protocol for other reasons
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01030796

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: James D Lane, Ph.D. Duke University
  More Information

Responsible Party: James D. Lane, Ph.D., Professor, Duke University School of Medicine Identifier: NCT01030796     History of Changes
Other Study ID Numbers: Pro00011009 (completed)
R01DK067486 ( US NIH Grant/Contract Award Number )
Study First Received: December 10, 2009
Last Updated: February 3, 2011

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on June 23, 2017